Related Experiment Video
Updated: Aug 12, 2026

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
COVID-19 Myocarditis: A Case Report, Overview of Diagnosis and Treatment
Sophia Kwon1, Eric Alter2, Sripal Bangalore2
1Divisions of Pulmonary, Critical Care and Sleep Medicine.
Insights
This study reports a rare case of COVID-19-induced myocarditis successfully treated with dexamethasone. This finding offers a potential therapeutic option for severe cardiac complications of coronavirus disease 2019.
Area of Science:
- Cardiology
- Infectious Diseases
- Immunology
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has resulted in a global pandemic with significant mortality.
- Myocarditis is a recognized but rare complication of COVID-19, often associated with severe disease progression and high mortality rates.
Observation:
- A case of COVID-19-induced myocarditis is presented, highlighting severe respiratory compromise requiring intubation.
- The patient experienced a catastrophic worsening of disease, a pattern observed in severe COVID-19 cases with cardiac involvement.
Findings:
- The patient with COVID-19-induced myocarditis was successfully treated with dexamethasone.
- This case suggests dexamethasone may be an effective therapeutic intervention for this specific complication.
Implications:
- Dexamethasone could represent a viable treatment strategy for COVID-19 patients presenting with myocarditis.
- Further research is warranted to confirm the efficacy and optimal use of dexamethasone in managing COVID-19-related myocarditis.
Abstract:
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), emerged in Wuhan, China, and rapidly led to a global pandemic that affected 213 countries, more than 5.8 million cases, and 360,000 deaths worldwide as of May 28, 2020. The United States currently has the highest number of COVID-19 cases in the world and contributes to nearly a third of the global death rate. The prevalence of COVID myocarditis is unclear but generally considered rare, with estimates up to 7% of COVID-related deaths. However, these patients suffered catastrophic worsening disease with respiratory compromise requiring intubation and often death. We report the case of a patient with COVID-19-induced myocarditis who was successfully treated with dexamethasone and review the literature.
More Related Videos
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Pericarditis III: Medical Management
Cardiomyopathy I: Introduction and Classification

